BioSpace News Archive

Immuron Limited, an Australian based and globally integrated biopharmaceutical company is pleased to announce that our Chief Executive Officer, Steven Lydeamore has been invited to present at the Emerging Growth Conference on June 13th, 2024.

MediciNova, Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 for the prevention of metastasis in various cancers including pancreatic cancer, lung cancer, breast cancer, colorectal cancer, melanoma, and ovarian cancer.

With new features that make it faster and easier to use, Novoxel Inc. announces the launch of Tixel 2® to the USA.

PathMaker Neurosystems Inc. announced that it has received a funding award of $2.16 million from the Congressionally Directed Medical Research Program at the United States Department of Defense’s U.S. Army Medical Research and Development Command, as part of its FY23 Amyotrophic Lateral Sclerosis Research Program Pilot Clinical Trial Award.

Immutep Limited ACN 009 237 889 is pleased to announce the successful completion of its institutional placement and the institutional component of its 1 for 16 pro rata accelerated non-renounceable entitlement offer of new fully paid ordinary shares in Immutep.

Mesa Laboratories, Inc., a global leader in the design and manufacture of life science tools and critical quality control solutions, announced results for its fourth fiscal quarter and fiscal year ended March 31, 2024.

Valneva SE, a specialty vaccine company, announced the availability of documentation for its Combined General Meeting to be held on June 26, 2024 at 2:00 p.m. CEST at the Sofitel Lyon Bellecour Hotel, 20 quai du Docteur Gailleton, 69002 Lyon.

Ipsen announced new late-breaking data at the European Association for the Study of the Liver Congress demonstrating the enduring efficacy of elafibranor in managing disease progression after 78 weeks of treatment.

Virion Therapeutics, LLC announced positive immunologic and continued safety and tolerability data, from the first-ever human study of its novel, first-in-class, checkpoint modifier immunotherapy, VRON-0200, for HBV functional cure, presented by Professor Ed Gane, M.D., from the University of Auckland, as a late breaker at the EASL Congress 2024 in Milan, Italy.

Vir Biotechnology, Inc. announced new preliminary data from its Phase 2 SOLSTICE hepatitis delta clinical trial evaluating tobevibart, an investigational monoclonal antibody, and elebsiran, an investigational small interfering ribonucleic acid, for the treatment of people living with chronic hepatitis delta.